Skip to content
    Case Study

    University of Oxford:
    Optimizing a new enzymatic assay in just 3 weeks

    How the University of Oxford used Synthace DOE to rapidly develop a new biochemical assay, and run experiments previously thought impossible.

    Try Synthace DOE Request a Demo
    University of Oxford - Interview with Adam
    hero-mask_desktop

    At a glance

    • 10 factors investigated
    • 3 weeks to run 2 experiment iterations and assay validation
    • 0.59 Z' value of optimized assay (n=128)
    CHALLENGES

    Costly, time-consuming methods

    The team at Oxford wanted to develop a new  biochemical assay for RecBCD - a DNA-damage repair enzyme that drives antibiotic resistance evolution. But due to the poor economic incentives for commercial antibiotic development, they couldn't justify the time-consuming and costly challenges of  traditional biochemical assay optimization, where you change one variable at a time.

    There was a growing need for new methodologies that generate information-rich datasets rapidly with reduced resources.

    oxford-university-solution
    SOLUTION

    Automated DOEs with Synthace

    The team at Oxford turned to Design of Experiments (DOE)—a robust methodology for investigating multiple variables at a time. 

    With the Synthace team's DOE expertise, they designed 2 experiments. Then thanks to Synthace's software, despite never having run the assay before, they were able to instantly translate their DOE designs into automation instructions. Then, they used JMP to do an analytical deep-dive.

    oxford-university-results (1)
    Results

    Identification of key performance factors

    After experiment iteration 1 (4 factors): They identified optimal MgCl2:ATP ratios for the assay (enhancing nuclease activity).

    After experiment iteration 2 (10 factors): They identified both non impactful and high performance factors using Zʼ as a response.

    Adam-Winnifreth-pebble

    "This was just such a rewarding way to work and do science, to iterate so rapidly."

    Adam Winnifrith 
    Ex-University of Oxford, Founder of Evolvere Biosciences

    Read the paper and the full story